Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors

National Medical Journal of China

Volumn 86, Issue 43, 2006, Pages 3064-3067

  Wan, De Sen ^a   Wu, Xiao Jun ^a   Pan, Zhi Zhong ^a   Zhou, Zhi Wei ^a   Chen, Gong ^a   Li, Li Ren ^a   Lu, Zhen Hai ^a   Ding, Pei Rong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Drug therapy; Gastrointestinal neoplasms

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INOPERABLE CANCER; LEG EDEMA; LEUKOPENIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NAUSEA; ORBIT EDEMA; PREOPERATIVE CARE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR BLEEDING; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PIPERAZINES; PREMEDICATION; PREOPERATIVE CARE; PYRIMIDINES; RETROSPECTIVE STUDIES;

EID: 33846417655     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mazur MT, Clark HB. Gastric stromal tumors: reap-praisal of histogenesis. Am J Surg Pathol, 1983, 7: 507-519.
2. Chinese source. 2005, 9: 161-163.
3. Duffaud F, Blay JY. Gastrointestinal stromal tumors: biology and treatment. Oncology, 2003, 65: 187-197.
4. Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol, 2002, 3: 655-664.
5. Dematteo RP, Heinrich MC, El- Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol, 2002, 33: 466-477.
6. Sarlomo Rikala M, Kovatich At, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol, 1998, 11: 728-734.
7. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol, 2002, 33: 459-465.
8. Rossi CR, Mocellin S, Mencarell R, et al. Gastrointestinal stomal tumors from a surgical to a molecular approach. Int J Cancer, 2003, 107: 171-176.
9. Chinese source. 2004, 25:229-231.
10. Chinese source. 2004, 25: 241-243.
11. Chinese source. 2003, 6: 288-291.
12. Frolov A, Chahwan S, Ochs M, et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther, 2003, 2: 699-709.
13. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs, 2003, 63: 513-522.
14. Bauer S, Corless CL, Hinrich MC, et al. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol, 2003, 51: 261-265.
15. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof' of concept and therapeutic implications. Am J Surg Pathol, 2004, 28: 889-294.
16. Christophe B, Magali T, Julien T, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell- dependent antitumor effects. J Clin Invest, 2004, 114: 379-388.
17. Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347: 472-480.
18. Chinese source. 2005,37:320-324.
19. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol, 2003, 21: 4342-4349.
20. Neuhans SJ, Clark MA, Hayes AJ, et al. Surgery for gastrointestinal stomal tumor in the post-imatinib era. ANZ J Surg, 2005, 75: 165-172.